Ipilimumab for stage unresectable III/IV melanoma: Brazilian experience in an expanded access program.
Rafael Schmerling
Consultant or Advisory Role - Bristol-Myers Squibb
Expert Testimony - Bristol-Myers Squibb
Daniel Herchenhorn
No relevant relationships to disclose
Jose Augusto Rinck
No relevant relationships to disclose
Veridiana Pires De Camargo
Honoraria - Bristol-Myers Squibb
Johnny Camargo
No relevant relationships to disclose
Sergio Vicente Serrano
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Sergio Jobim Azevedo
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Carlos H. Barrios
No relevant relationships to disclose
Jose Getulio Martins Segalla
No relevant relationships to disclose
Vanessa Dybal Bertoni
Honoraria - Bristol-Myers Squibb
Antonio C. Buzaid
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb